Clinical Trial Update: A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating olaratumab in combination with doxorubicin and ifosfamide for advanced or metastatic soft tissue sarcoma has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• IFOSFAMIDE (IFOSFAMIDE)
• Olaratumab (LY3012207) (olaratumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Soft Tissue Sarcoma | Phase 1 | Status: COMPLETED | Results posted: 2020-09-10